Coherus Oncology, Inc. ( CHRS) - Key Metrics
CHRS Revenue per Share metrics
| Date | Revenue per Share | Net Income per Share | Operating Cash Flow | Free Cash Flow per Share |
|---|---|---|---|---|
| 2026Q2 | $0.09 | -$0.13 | -$0.77 | -$0.77 |
| 2026Q1 | $0.09 | -$0.28 | -$0.42 | -$0.42 |
| 2025Q4 | $0.11 | -$0.31 | -$0.16 | -$0.16 |
| 2025Q3 | $0.10 | -$0.30 | -$0.40 | -$0.40 |
| 2025Q2 | $0.09 | -$0.36 | -$0.40 | -$0.40 |
CHRS Payout ratio and Price per Earnings ratio
| Date | Payout ratio | PE ratio |
|---|---|---|
| 2026Q2 | 0% | -2.69 |
| 2026Q1 | 0% | -1.51 |
| 2025Q4 | 0% | -1.15 |
| 2025Q3 | 0% | -1.37 |
| 2025Q2 | 0% | -0.47 |
CHRS
Price: $1.07
52 week price:
Earnings Per Share: -1.24 USD
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 749400
Ebitda: -55.8 millionMarket Capitalization: 173.0 million